Evaluation of ERG responsive proteome in prostate cancer

Evaluation of ERG responsive proteome in prostate cancer

Item
http://www.wikidata.org/entity/Q33822319
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsDistinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticityERG oncoprotein inhibits ANXA2 expression and function in prostate cancerFunctional analysis of keratinocyte and fibroblast gene expression in skin and keloid scar tissue based on deviation analysis of dynamic capabilities.New concepts concerning prostate cancer screening.Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomyQuantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
P2860

Evaluation of ERG responsive proteome in prostate cancer

Item
http://www.wikidata.org/entity/Q33822319
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evaluation of ERG responsive proteome in prostate cancer
@ast
Evaluation of ERG responsive proteome in prostate cancer
@en
type
label
Evaluation of ERG responsive proteome in prostate cancer
@ast
Evaluation of ERG responsive proteome in prostate cancer
@en
prefLabel
Evaluation of ERG responsive proteome in prostate cancer
@ast
Evaluation of ERG responsive proteome in prostate cancer
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Evaluation of ERG responsive proteome in prostate cancer
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932